Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Merck reports positive Phase III results of insomnia drug

PBR Staff Writer Published 07 February 2012

Merck has provided an update on the development program for Suvorexant, the company's investigational orexin receptor antagonist, used for the treatment of insomnia.

The multicenter randomized double-blind placebo-controlled Phase III studies evaluated Suvorexant compared to placebo in adult patients aged 18 years and older.

In the trials, the primary endpoint was change from baseline in subjective total sleep time and time to sleep onset, wake time after persistent sleep onset, and latency to onset of persistent sleep at one and three months.

Based on the positive results from the two pivotal Phase III efficacy trials of Suvorexant, Merck plans to file a New Drug Application (NDA) with the US Food and Drug Administration (FDA) in 2012.

Merck Research Laboratories president Peter S Kim said Suvorexant selectively targets a crucial pathway involved in promoting sleep.

"We are enthusiastic about the potential of this investigational medicine, and look forward to sharing the results from these studies with the medical community," Kim added.

 

 

Comments
Post a comment

Comments may be moderated for spam, obscenities or defamation.